AU1405001A - Treatment of diseases - Google Patents

Treatment of diseases

Info

Publication number
AU1405001A
AU1405001A AU14050/01A AU1405001A AU1405001A AU 1405001 A AU1405001 A AU 1405001A AU 14050/01 A AU14050/01 A AU 14050/01A AU 1405001 A AU1405001 A AU 1405001A AU 1405001 A AU1405001 A AU 1405001A
Authority
AU
Australia
Prior art keywords
diseases
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU14050/01A
Inventor
Craig Alexander Mcardle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Publication of AU1405001A publication Critical patent/AU1405001A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
AU14050/01A 1999-11-17 2000-11-17 Treatment of diseases Abandoned AU1405001A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9927215 1999-11-17
GBGB9927215.5A GB9927215D0 (en) 1999-11-17 1999-11-17 Hormone receptor expression
PCT/GB2000/004385 WO2001036446A2 (en) 1999-11-17 2000-11-17 Use of g-protein coupled receptors (gpcrs) and modified gpcrs for the treatment of diseases

Publications (1)

Publication Number Publication Date
AU1405001A true AU1405001A (en) 2001-05-30

Family

ID=10864694

Family Applications (1)

Application Number Title Priority Date Filing Date
AU14050/01A Abandoned AU1405001A (en) 1999-11-17 2000-11-17 Treatment of diseases

Country Status (3)

Country Link
AU (1) AU1405001A (en)
GB (1) GB9927215D0 (en)
WO (1) WO2001036446A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1273309A1 (en) * 2001-07-05 2003-01-08 Georg-August Universität Göttingen Gene therapeutic method for the treatment of GnRH-receptor positve carcinomas through GnRH induced tumor cell specific activation of a therapeutic gene, corresponding nucleic acids and vectors
DE10292896D2 (en) * 2001-07-05 2004-07-01 Univ Goettingen Georg August Gene therapy method for the treatment of GnRH receptor-positive carcinomas by GnRH-induced tumor cell-specific activation of a therapeutic gene, associated nucleic acid constructs and vectors
US20030108928A1 (en) * 2001-10-09 2003-06-12 Millennium Pharmaceuticals, Inc. MID 241 receptor, a novel G-protein coupled receptor
EP2216340B1 (en) 2007-10-17 2012-12-12 Universidad De Córdoba Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligonucleotide pairs for detection thereof by pcr
WO2016111657A1 (en) * 2015-01-08 2016-07-14 Iyison Necla Birgul Use of allatostatin receptor in cancer treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
DK0647275T3 (en) * 1992-06-23 2005-01-24 Sinai School Medicine Cloning and expression of the gonatotropin-releasing hormone receptor

Also Published As

Publication number Publication date
WO2001036446A3 (en) 2002-05-10
GB9927215D0 (en) 2000-01-12
WO2001036446A2 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
AU2002210385A1 (en) Furazanyl-triazole derivates for the treatment of diseases
AU5215300A (en) Dental treatment area
AU1356201A (en) Treatment of hyperproliferative disorders
AU3896900A (en) Treatment of pain
HUP0104963A3 (en) Compositions for the treatment of skin diseases
AU5547000A (en) Novel treatment
AU7106300A (en) Treatment of skin disorders
GB9927757D0 (en) Treatment of autoimmune diseases
AU4215499A (en) Treatment of neurodegenerative diseases
AU2432001A (en) Treatment of mental conditions including depression
AU4556800A (en) Novel treatment
AU3004000A (en) Methods for the treatment of apolipoprotein e related diseases
AU3760900A (en) Treatment of menstrual function
AU1405001A (en) Treatment of diseases
AU2080201A (en) Treatment of addiction disorders
AUPQ367699A0 (en) Treatment of cancer
AU5552400A (en) Treatment of cancer
AU2566201A (en) Compounds and methods for the treatment of pain
AU1618901A (en) Treatment of rosacea
AU2001267165A1 (en) Prevention and treatment of mycoplasma-associated diseases
AU5854799A (en) Novel treatment of neurodegenerative diseases
AU4598400A (en) Method of treatment
AU2683500A (en) Compositions for the treatment of pain
AU2382601A (en) Novel method of treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase